Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Feb;18(2):179-87.
doi: 10.1007/s00520-009-0642-2. Epub 2009 May 6.

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Debra L Barton  1 , Gamini S Soori, Brent A Bauer, Jeff A Sloan, Patricia A Johnson, Cesar Figueras, Steven Duane, Bassam Mattar, Heshan Liu, Pamela J Atherton, Bradley Christensen, Charles L Loprinzi
Affiliations
Clinical Trial

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Debra L Barton et al. Support Care Cancer. 2010 Feb.

Abstract

Purpose: This pilot trial sought to investigate whether any of three doses of American ginseng (Panax quinquefolius) might help cancer-related fatigue. A secondary aim was to evaluate toxicity.

Methods: Eligible adults with cancer were randomized in a double-blind manner, to receive American ginseng in doses of 750, 1,000, or 2,000 mg/day or placebo given in twice daily dosing over 8 weeks. Outcome measures included the Brief Fatigue Inventory, vitality subscale of the Medical Outcome Scale Short Form-36 (SF-36), and the Global Impression of Benefit Scale at 4 and 8 weeks.

Results: Two hundred ninety patients were accrued to this trial. Nonsignificant trends for all outcomes were seen in favor of the 1,000- and 2,000-mg/day doses of American ginseng. Area under the curve analysis of activity interference from the Brief Fatigue Inventory was 460-467 in the placebo group and 750 mg/day group versus 480-551 in the 1,000- and 2,000-mg/day arms, respectively. Change from baseline in the vitality subscale of the SF-36 was 7.3-7.8 in the placebo and the 750-mg/day arm, versus 10.5-14.6 in the 1,000- and 2,000-mg/day arms. Over twice as many patients on ginseng perceived a benefit and were satisfied with treatment over those on placebo. There were no significant differences in any measured toxicities between any of the arms.

Conclusion: There appears to be some activity and tolerable toxicity at 1,000-2,000 mg/day doses of American ginseng with regard to cancer-related fatigue. Thus, further study of American ginseng is warranted.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CONSORT diagram
Fig. 2
Fig. 2
Perception of benefit
See this image and copyright information in PMC

References

    1. NCCN Cancer Related Fatigue Clinical Practice Guidelines in Oncology V.1. 2003 http://www.nccn.org/ - PubMed
    1. Mock V. Fatigue management, evidence and guidelines for practice. Cancer. 2001;92(6):1699–1707. doi:10.1002/1097-0142(20010915)92:6+<1699::AID-CNCR1500>3.0.CO;2-9. - PubMed
    1. Fulton C, Knowles G. Cancer fatigue. Eur J Cancer Care (Engl) 2000;9(3):167–171. - PubMed
    1. Gutstein HB. The biological basis of fatigue. Cancer. 2001;92(6):1678–1683. doi:10.1002/1097-0142(20010915)92:6+<1678::AID-CNCR1496>3.0.CO;2-R. - PubMed
    1. Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage. 2007;33(4):398–409. doi:10.1016/j.jpainsymman.2006.09.022. - PMC - PubMed

Publication types